Q2 Earnings Forecast for Longeveron Issued By Zacks Research

Longeveron Inc. (NASDAQ:LGVN) – Zacks Research boosted their Q2 2026 earnings estimates for shares of Longeveron in a research report issued to clients and investors on Thursday, May 14th. Zacks Research analyst B. Sorensen now forecasts that the company will post earnings per share of ($0.18) for the quarter, up from their previous forecast of ($0.22). The consensus estimate for Longeveron’s current full-year earnings is ($0.70) per share. Zacks Research also issued estimates for Longeveron’s Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.69) EPS, FY2027 earnings at ($0.71) EPS and FY2028 earnings at ($0.68) EPS.

Longeveron (NASDAQ:LGVN) last posted its earnings results on Wednesday, May 13th. The company reported ($0.19) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.19). Longeveron had a negative net margin of 1,844.49% and a negative return on equity of 202.41%. The firm had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.33 million.

LGVN has been the subject of several other reports. Maxim Group cut shares of Longeveron from a “buy” rating to a “hold” rating in a research report on Monday, May 11th. HC Wainwright lowered their price target on shares of Longeveron from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, May 4th. Wall Street Zen cut shares of Longeveron from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Longeveron in a research report on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $5.50.

Longeveron Stock Performance

Shares of NASDAQ:LGVN opened at $0.68 on Tuesday. The company has a market capitalization of $15.73 million, a price-to-earnings ratio of -0.60 and a beta of -0.31. Longeveron has a 12 month low of $0.48 and a 12 month high of $1.80. The firm’s 50-day moving average is $0.94 and its 200 day moving average is $0.72. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.05.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Longeveron stock. ADAR1 Capital Management LLC purchased a new stake in shares of Longeveron Inc. (NASDAQ:LGVN) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 200,000 shares of the company’s stock, valued at approximately $208,000. ADAR1 Capital Management LLC owned approximately 0.86% of Longeveron at the end of the most recent quarter. 10.01% of the stock is owned by institutional investors.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.